Carmel Diagnostics has developed a method for measuring the oxidative stress (OS) of biological liquids, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured using thermochemiluminescence (TCL) technology. The company's lead product is focused on the process of embryo selection in in-vitro fertilization (IVF). The Fertissimo TCL Analyzer is a noninvasive embryo selection system for the IVF market, offering up to a 20% increase in successful IVF pregnancies. Effective embryo viability assessment significantly improves the success rate and reduces the risk of multiple births. Carmel Diagnostics has performed two successful proof-of-concept studies covered by peer-reviewed articles on the applications of risk stratification for patients with congestive heart failure and embryo selection in the IVF process, and is currently performing a clinical validation study for the IVF application. Carmel Diagnostics was awarded a Horizon 2020 phase-2 grant.